Roche reached an agreement to acquire LumiraDx’s point-of-care testing technology, the companies announced on Dec. 29. Roche will pay $295 million upfront and an additional amount up to $55 million to ...

TORONTO, ON / ACCESSWIRE / March 7, 2024 / Lumira Ventures, a life sciences investment firm dedicated to supporting healthcare innovation and patient impact, is proud to announce several significant ...

The Lumira Seed is available at certain steps of the Bizzy Bear's battle pass-style crafting recipe system. Combined with the rarity of its ingredients, the process of getting the Lumira Seed is quite ...

Canadian life sciences fund Lumira Ventures has raised a major tranche of cash as it looks to funnel an extra $220 million into the sector. Its Fund IV also comes with some extra swag: The VC has tied ...

Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase™ platform gene editors to build a pipeline of treatments for serious genetic diseases. Gene ...

Lumira Capital Announces Investment in enGene Inc. TORONTO, ONTARIO–(Marketwired – Aug. 2, 2013) – enGene Inc., a pre-clinical stage biopharmaceutical company developing a platform technology for the ...

Toronto-based Lumira Ventures has raised $276 million CAD ($220 million USD) for Fund IV, which Lumira claims is “the largest institutional life sciences venture capital fund ever raised in Canada.” ...

Lumira Ventures, one of Canada’s top investors in private health sciences startups, is launching a hedge fund to bet on publicly traded companies it believes have been oversold during the sector’s ...

During the past 18 months Lumira Ventures completed 8 exit transactions and portfolio companies received 2 FDA new product approvals and raised over US$800M via IPOs and public and private financings ...

TORONTO, ON / ACCESSWIRE / January 10, 2025 / Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is ...